AR062207A1 - Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer. - Google Patents

Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.

Info

Publication number
AR062207A1
AR062207A1 ARP070103435A ARP070103435A AR062207A1 AR 062207 A1 AR062207 A1 AR 062207A1 AR P070103435 A ARP070103435 A AR P070103435A AR P070103435 A ARP070103435 A AR P070103435A AR 062207 A1 AR062207 A1 AR 062207A1
Authority
AR
Argentina
Prior art keywords
pyridazin
imidazo
benzamide
substituent
hydrogen atom
Prior art date
Application number
ARP070103435A
Other languages
English (en)
Inventor
Sakai Nozomu
Imamura Shinichi
Miyamoto Naoki
Hirayama Takaharu
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR062207A1 publication Critical patent/AR062207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un agente farmacéutico que contiene el compuesto que es un inhibidor de quinasa (VEGFR, VEGFR2, PDGFR, Raf), un inhibidor de angiogénesis, un agente para la prevencion o el tratamiento del cáncer, un inhibidor del crecimiento del cáncer o un supresor de la metástasis cancerosa. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en donde anillo Y es un grupo cíclico opcionalmente sustituido; X es -O-, -S-, -S(O)-, -S(O)2- o -NR- (en donde R es un átomo de hidrogeno o un sustituyente); R1 es un átomo de hidrogeno o un sustituyente; R2 es un átomo de hidrogeno o un sustituyente; R3 es un átomo de hidrogeno o un sustituyente; R4 es un átomo de hidrogeno o un sustituyente; con la condicion de que cuando R1 es distinto de un amino opcionalmente sustituido, anillo Y sea un grupo cíclico sustituido con un amino opcionalmente sustituido, en donde el grupo cíclico también está opcionalmente sustituido, y que se excluyan [6-(feniltio)imidazo(1,2-b]piridazin-2- il]carbamato de metilo, [6-(fenilsulfinil)imidazo[1,2-b]piridazin-2-il]carbamato de metilo, 6-(4-acetamidofenoxi) imidazo[1,2-b]piridazin-2-carboxilato de etilo, 6-[4-(4-acetilpiperazin-1-il)fenoxi]imidazo[1,2- b]piridazin-2-carboxilato de etilo, N- [1-(imidazo[1,2-b]piridazin-6-ilamino)-2,5-dioxo- 1,2, 5, 6,7, 8-hexahidroquinolin-3-il]benzamida, N-[1-(imidazo[1,2-b]piridazin-6-ilamino)-7,7-dimetil-2,5- dioxo-1,2,5,6,7,8-hexahidroquinolin-3-il]benzamida, N-[1-(imidazo[1,2-b]piridazin-6-ilamino)- 2,5-dioxo-2,5,6,7- tetrahidro-1H-ciclopenta[b]piridin-3-il]benzamida, N-[1-(imidazo[1,2-b]piridazin-6-ilamino)-7-metil-2,5-dioxo- 1,2,5,6,7,8-hexahidroquinolin-3-il]benzamida, N-[(5E)-5-(imidazo[1,2-b]piridazin-6-ilhidrazono)-7-metil-2-oxo-4a,5, 6,7,8,8a-hexahidro-2H-cromen-3-il)benzamida, (6R, 7R)-3- (imidazo[1,2-b]piridazin-6-iltio)-8-oxo-7-[(fenilacetil)amino]-5-tia-1-azabiciclo[4,2,0]oct-2-en-2-carboxilato de 4-metoxibencilo, 4-[(3-metoxi-2-fenilimidazo[1,2-b)piridazin-6-il)tio]-N,N- dimetilanilina, 3-metoxi-6-(3-nitrofenoxi)-2-fenilimidazo[1,2-b]piridazina, 3-[(3-metoxi-2-fenilimidazo[1,2-b]piridazin-6-il)oxi)anilina, y 3-[(3-metoxi-2-fenilimidazo[1,2-b]piridazin-6-il)oxi]-N,N-dimetilanilina, o una de sus sales.
ARP070103435A 2006-08-04 2007-08-03 Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer. AR062207A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006331230 2006-12-07
JP2007144072 2007-05-30

Publications (1)

Publication Number Publication Date
AR062207A1 true AR062207A1 (es) 2008-10-22

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103435A AR062207A1 (es) 2006-08-04 2007-08-03 Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.

Country Status (18)

Country Link
US (4) US8044049B2 (es)
EP (1) EP2049541B1 (es)
JP (1) JP5238697B2 (es)
KR (1) KR20090047509A (es)
AR (1) AR062207A1 (es)
AU (1) AU2007279595A1 (es)
BR (1) BRPI0714665A2 (es)
CA (1) CA2659971A1 (es)
CL (1) CL2007002261A1 (es)
CO (1) CO6150183A2 (es)
CR (1) CR10607A (es)
IL (1) IL196799A0 (es)
MA (1) MA30651B1 (es)
MX (1) MX2009001349A (es)
NO (1) NO20090986L (es)
PE (1) PE20080538A1 (es)
TW (1) TW200817409A (es)
WO (1) WO2008016192A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8058274B2 (en) * 2007-08-17 2011-11-15 Icagen, Inc. Heterocycles as potassium channel modulators
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
JP5576802B2 (ja) 2008-02-28 2014-08-20 ノバルティス アーゲー Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
MX2011003553A (es) 2008-10-02 2011-05-25 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
JP5600111B2 (ja) 2008-10-22 2014-10-01 アレイ バイオファーマ、インコーポレイテッド ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物
JP5579619B2 (ja) * 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2370428B1 (en) 2008-12-11 2016-08-10 Respivert Limited P38 map kinase inhibitors
WO2010072632A1 (en) 2008-12-24 2010-07-01 Syngenta Limited Methods for the preparation of aryl amides
JP5059977B2 (ja) 2009-02-10 2012-10-31 アストラゼネカ アクチボラグ トリアゾロ［４，３−ｂ］ピリダジン誘導体および前立腺癌のためのそれらの使用
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5583845B2 (ja) 2010-04-28 2014-09-03 ブリストル−マイヤーズ スクイブ カンパニー イミダゾピリダジニル化合物および癌に対するそれらの使用
ES2620644T3 (es) * 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
EP2992112B1 (en) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US9988386B2 (en) 2013-05-30 2018-06-05 Kata Pharmaceuticals, Inc. Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
JP2016540773A (ja) * 2013-12-06 2016-12-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
SI3623362T1 (sl) 2013-12-13 2023-03-31 Eurochem Agro Gmbh Gnojilna zmes, ki vsebuje nitrifikacijski inhibitor
US10253045B2 (en) 2014-11-26 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
JPWO2016093299A1 (ja) * 2014-12-10 2017-09-21 千寿製薬株式会社 水性液剤
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PL3800189T3 (pl) 2016-05-18 2023-10-23 Loxo Oncology, Inc. Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
EA201990158A1 (ru) 2016-06-29 2019-05-31 Орион Корпорейшн Производные бензодиоксана и их фармацевтическое применение
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018094005A1 (en) * 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021075477A1 (ja) * 2019-10-16 2021-04-22 国立大学法人京都大学 運動神経細胞変性阻害剤
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3210985A1 (en) * 2021-03-12 2022-09-15 Sarah KANE Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-based alpha inhibitors and their uses
WO2024088379A1 (zh) * 2022-10-27 2024-05-02 香港科技大学 肿瘤的治疗或预防方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001478A1 (en) 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
WO1989001333A1 (en) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6797823B1 (en) 1999-01-22 2004-09-28 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
SK287142B6 (sk) 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
DE602004006536T2 (de) 2003-12-31 2008-01-31 Schering-Plough Ltd. Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
AU2005301568B2 (en) * 2004-11-08 2011-06-09 Msd K.K. Novel fused imidazole derivative
EP1832588A4 (en) * 2004-12-28 2009-09-02 Takeda Pharmaceutical IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND

Also Published As

Publication number Publication date
US20100168424A1 (en) 2010-07-01
JP5238697B2 (ja) 2013-07-17
KR20090047509A (ko) 2009-05-12
EP2049541B1 (en) 2015-09-23
US8034812B2 (en) 2011-10-11
CA2659971A1 (en) 2008-02-07
WO2008016192A2 (en) 2008-02-07
CO6150183A2 (es) 2010-04-20
CR10607A (es) 2009-03-12
WO2008016192A3 (en) 2008-05-08
CL2007002261A1 (es) 2008-05-02
AU2007279595A2 (en) 2009-03-19
IL196799A0 (en) 2009-11-18
MA30651B1 (fr) 2009-08-03
MX2009001349A (es) 2009-04-17
AU2007279595A1 (en) 2008-02-07
PE20080538A1 (es) 2008-06-18
JP2009545583A (ja) 2009-12-24
US8044049B2 (en) 2011-10-25
EP2049541A2 (en) 2009-04-22
US8273741B2 (en) 2012-09-25
TW200817409A (en) 2008-04-16
US20100273788A1 (en) 2010-10-28
NO20090986L (no) 2009-05-04
US20090137595A1 (en) 2009-05-28
BRPI0714665A2 (pt) 2012-03-13
US20090306374A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
AR062207A1 (es) Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
PH12015500666A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
EA200901608A1 (ru) Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
JP2009541223A5 (es)
AR085099A1 (es) Derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inhibidores de fosfodiesterasas
CA2687265A1 (en) P70 s6 kinase inhibitors
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
US8912181B2 (en) Bicyclic compound or salt thereof
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
WO2015151006A1 (en) Substituted purine compounds as btk inhibitors
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
EA201892460A1 (ru) Производные аденина как ингибиторы протеинкиназ
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)
MX2021010131A (es) Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
BR112015026132A2 (pt) acoplamento de pd-catalizado de pirazol amidas
MX2021010295A (es) Nuevo inhibidor de cinasa pan-proteina de fibrosarcoma rapidamente acelerado (raf) y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure